Literature DB >> 32514071

AP-1 imprints a reversible transcriptional programme of senescent cells.

Ricardo Iván Martínez-Zamudio1,2,3, Pierre-François Roux1,2,4, José Américo N L F de Freitas1,2,5, Lucas Robinson1,2,5, Gregory Doré1,2, Bin Sun6,7, Dimitri Belenki8,9, Maja Milanovic8,10, Utz Herbig3, Clemens A Schmitt8,9,10,11, Jesús Gil6,7, Oliver Bischof12,13.   

Abstract

Senescent cells affect many physiological and pathophysiological processes. While select genetic and epigenetic elements for senescence induction have been identified, the dynamics, epigenetic mechanisms and regulatory networks defining senescence competence, induction and maintenance remain poorly understood, precluding the deliberate therapeutic targeting of senescence for health benefits. Here, we examined the possibility that the epigenetic state of enhancers determines senescent cell fate. We explored this by generating time-resolved transcriptomes and epigenome profiles during oncogenic RAS-induced senescence and validating central findings in different cell biology and disease models of senescence. Through integrative analysis and functional validation, we reveal links between enhancer chromatin, transcription factor recruitment and senescence competence. We demonstrate that activator protein 1 (AP-1) 'pioneers' the senescence enhancer landscape and defines the organizational principles of the transcription factor network that drives the transcriptional programme of senescent cells. Together, our findings enabled us to manipulate the senescence phenotype with potential therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32514071      PMCID: PMC7899185          DOI: 10.1038/s41556-020-0529-5

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.213


  44 in total

1.  Histone H3K27ac separates active from poised enhancers and predicts developmental state.

Authors:  Menno P Creyghton; Albert W Cheng; G Grant Welstead; Tristan Kooistra; Bryce W Carey; Eveline J Steine; Jacob Hanna; Michael A Lodato; Garrett M Frampton; Phillip A Sharp; Laurie A Boyer; Richard A Young; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-24       Impact factor: 11.205

2.  Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells.

Authors:  Moussa Benhamed; Utz Herbig; Tao Ye; Anne Dejean; Oliver Bischof
Journal:  Nat Cell Biol       Date:  2012-02-26       Impact factor: 28.824

3.  Latent enhancers activated by stimulation in differentiated cells.

Authors:  Renato Ostuni; Viviana Piccolo; Iros Barozzi; Sara Polletti; Alberto Termanini; Silvia Bonifacio; Alessia Curina; Elena Prosperini; Serena Ghisletti; Gioacchino Natoli
Journal:  Cell       Date:  2013-01-17       Impact factor: 41.582

4.  Senescence-associated reprogramming promotes cancer stemness.

Authors:  Maja Milanovic; Dorothy N Y Fan; Dimitri Belenki; J Henry M Däbritz; Zhen Zhao; Yong Yu; Jan R Dörr; Lora Dimitrova; Dido Lenze; Ines A Monteiro Barbosa; Marco A Mendoza-Parra; Tamara Kanashova; Marlen Metzner; Katharina Pardon; Maurice Reimann; Andreas Trumpp; Bernd Dörken; Johannes Zuber; Hinrich Gronemeyer; Michael Hummel; Gunnar Dittmar; Soyoung Lee; Clemens A Schmitt
Journal:  Nature       Date:  2017-12-20       Impact factor: 49.962

Review 5.  The selection and function of cell type-specific enhancers.

Authors:  Sven Heinz; Casey E Romanoski; Christopher Benner; Christopher K Glass
Journal:  Nat Rev Mol Cell Biol       Date:  2015-02-04       Impact factor: 94.444

6.  BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance.

Authors:  Nilgun Tasdemir; Ana Banito; Jae-Seok Roe; Direna Alonso-Curbelo; Matthew Camiolo; Darjus F Tschaharganeh; Chun-Hao Huang; Ozlem Aksoy; Jessica E Bolden; Chi-Chao Chen; Myles Fennell; Vishal Thapar; Agustin Chicas; Christopher R Vakoc; Scott W Lowe
Journal:  Cancer Discov       Date:  2016-04-20       Impact factor: 39.397

Review 7.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

8.  HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia.

Authors:  Taranjit Singh Rai; John J Cole; David M Nelson; Dina Dikovskaya; William J Faller; Maria Grazia Vizioli; Rachael N Hewitt; Orchi Anannya; Tony McBryan; Indrani Manoharan; John van Tuyn; Nicholas Morrice; Nikolay A Pchelintsev; Andre Ivanov; Claire Brock; Mark E Drotar; Colin Nixon; William Clark; Owen J Sansom; Kurt I Anderson; Ayala King; Karen Blyth; Peter D Adams
Journal:  Genes Dev       Date:  2014-12-15       Impact factor: 11.361

9.  Long noncoding RNA PANDA and scaffold-attachment-factor SAFA control senescence entry and exit.

Authors:  Pavan Kumar Puvvula; Rohini Devi Desetty; Pascal Pineau; Agnés Marchio; Anne Moon; Anne Dejean; Oliver Bischof
Journal:  Nat Commun       Date:  2014-11-19       Impact factor: 14.919

Review 10.  The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy.

Authors:  Markus Schosserer; Johannes Grillari; Michael Breitenbach
Journal:  Front Oncol       Date:  2017-11-23       Impact factor: 6.244

View more
  29 in total

1.  AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells.

Authors:  Natacha Comandante-Lou; Douglas G Baumann; Mohammad Fallahi-Sichani
Journal:  Cell Rep       Date:  2022-08-02       Impact factor: 9.995

Review 2.  Targeting CDK4 and CDK6 in cancer.

Authors:  Shom Goel; Johann S Bergholz; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2022-03-18       Impact factor: 69.800

Review 3.  Chromatin basis of the senescence-associated secretory phenotype.

Authors:  Xue Hao; Chen Wang; Rugang Zhang
Journal:  Trends Cell Biol       Date:  2022-01-07       Impact factor: 21.167

4.  HDAC4 degradation during senescence unleashes an epigenetic program driven by AP-1/p300 at selected enhancers and super-enhancers.

Authors:  Eros Di Giorgio; Harikrishnareddy Paluvai; Emiliano Dalla; Liliana Ranzino; Alessandra Renzini; Viviana Moresi; Martina Minisini; Raffaella Picco; Claudio Brancolini
Journal:  Genome Biol       Date:  2021-05-10       Impact factor: 13.583

5.  Glial AP1 is activated with aging and accelerated by traumatic brain injury.

Authors:  China N Byrns; Janani Saikumar; Nancy M Bonini
Journal:  Nat Aging       Date:  2021-07-08

6.  Radiation-Induced Senescence in p16+/LUC Mouse Lung Compared to Bone Marrow Multilineage Hematopoietic Progenitor Cells.

Authors:  Michael W Epperly; Donna Shields; Renee Fisher; Wen Hou; Hong Wang; Diala Fatima Hamade; Amitava Mukherjee; Joel S Greenberger
Journal:  Radiat Res       Date:  2021-09-01       Impact factor: 3.372

7.  Unveiling E2F4, TEAD1 and AP-1 as regulatory transcription factors of the replicative senescence program by multi-omics analysis.

Authors:  Yuting Wang; Liping Liu; Yifan Song; Xiaojie Yu; Hongkui Deng
Journal:  Protein Cell       Date:  2022-01-12       Impact factor: 15.328

8.  The m6A mRNA demethylase FTO in granulosa cells retards FOS-dependent ovarian aging.

Authors:  Zhong-Xin Jiang; Yi-Ning Wang; Zi-Yuan Li; Zhi-Hui Dai; Yi He; Kun Chu; Jia-Yi Gu; Yi-Xuan Ji; Ning-Xia Sun; Fu Yang; Wen Li
Journal:  Cell Death Dis       Date:  2021-07-27       Impact factor: 8.469

9.  Single-nuclear transcriptomics reveals diversity of proximal tubule cell states in a dynamic response to acute kidney injury.

Authors:  Louisa M S Gerhardt; Jing Liu; Kari Koppitch; Pietro E Cippà; Andrew P McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-06       Impact factor: 11.205

10.  The Cancer SENESCopedia: A delineation of cancer cell senescence.

Authors:  Fleur Jochems; Bram Thijssen; Giulia De Conti; Robin Jansen; Ziva Pogacar; Kelvin Groot; Liqin Wang; Arnout Schepers; Cun Wang; Haojie Jin; Roderick L Beijersbergen; Rodrigo Leite de Oliveira; Lodewyk F A Wessels; René Bernards
Journal:  Cell Rep       Date:  2021-07-27       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.